Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News BrightPath Bio, Cellistic join forces to advance iPSC-derived CAR-NKT cell therapy for multiple myeloma BrightPath Bio and Cellistic have entered into a collaboration aimed at advancing iPSC-derived CAR-NKT cell therapy. This partnership… byPallavi MadhirajuDecember 15, 2024